This Week in General Medicine — Jul 9, 2026

Welcome to This Week in General Medicine. This week we're covering four notable papers spanning the clinical efficacy and access barriers of modern pharmacotherapy, and the critical need for personalized standards in risk assessment. Let's dive in.

We begin with a theme that directly impacts daily primary care practice: balancing the clinical promise of advanced pharmacotherapy against the practical realities of treatment access and tolerability. Managing obesity has been transformed by a rapidly expanding therapeutic pipeline, but clinicians often struggle to navigate the trade-offs between weight loss efficacy, side effects, and long-term clinical benefits. To clarify these trade-offs, a systematic review and network meta-analysis published in the BMJ evaluated nineteen different weight-loss drugs across two hundred and sixty-two randomized controlled trials, encompassing nearly one hundred thousand participants [1]. The researchers analyzed outcomes over follow-up periods ranging from twelve to one hundred and seventy-two weeks, comparing these drugs to placebo, lifestyle modification alone, or other active agents. At the one-year mark, the analysis revealed that several medications produce substantial weight loss when compared to lifestyle modification alone. The most pronounced reductions were seen with tirzepatide, which led to a mean weight loss of nearly fifteen percent, and the combination of cagrilintide and semaglutide, known as CagriSema, which achieved an identical weight reduction of almost fifteen percent. Oral semaglutide led to a mean weight reduction of approximately eleven percent, while orforglipron and subcutaneous semaglutide both achieved reductions of roughly ten percent. Phentermine-topiramate followed closely with an eight percent reduction. The investigators also noted that emerging agents, such as ecnoglutide, mazdutide, and retatrutide, may produce similar or even greater weight reductions, ranging from thirteen to nearly fifteen percent, though the certainty of this evidence remains low to very low.

However, these impressive weight loss figures come with significant trade-offs in tolerability and safety. The meta-analysis demonstrated that the agents offering the greatest weight loss are often those most frequently discontinued due to adverse events. Moderate to high certainty evidence showed that treatment discontinuation was highest among patients taking orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide, with risk ratios for discontinuation ranging from roughly double to over four times that of control groups. Gastrointestinal adverse events were particularly prominent, with risk ratios increased by three- to four-fold for patients taking naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide. Fatigue was another major complaint, particularly with naltrexone-bupropion, which carried a nearly nine-fold increased risk of fatigue, translating to an absolute increase of three hundred and thirty-one additional cases per one thousand patients over one year. Orforglipron and CagriSema also increased fatigue risk by more than three-fold, adding around one hundred and ninety-two additional cases per one thousand patients, respectively. Furthermore, the quality of weight loss varied; tirzepatide reduced total fat mass the most, by over twenty-five percent, but it also caused the greatest reduction in lean mass, at over eight percent. When looking at hard clinical outcomes, the results were more sobering. Subcutaneous semaglutide was the only medication associated with a clear reduction in all-cause mortality, lowering the risk by nineteen percent, and myocardial infarction, reducing the risk by twenty-eight percent. However, these findings were largely driven by cardiovascular outcome trials conducted in high-risk populations. Both subcutaneous semaglutide and tirzepatide also reduced the risk of heart failure, cutting the risk by more than half. Crucially, none of the studied drugs convincingly reduced the risk of kidney failure, and none improved patient-reported quality of life beyond established minimally important thresholds. Across forty-three trials measuring quality of life, all mean differences were less than five points, falling short of the ten-point threshold required for a clinically meaningful improvement. These findings suggest that while these medications are highly effective for weight reduction, clinicians must carefully discuss the potential for side effects, lean mass loss, and the high likelihood of treatment discontinuation with their patients.

Even when a clinician and a patient agree on a treatment plan, systemic barriers can prevent the prescription from ever being filled. In a retrospective national cohort study published in JAMA, researchers investigated the frequency and consequences of formulary-related insurance rejections for single-source branded drugs in the United States [3]. Using the IQVIA Formulary Impact Analyzer, which captures anonymized, adjudicated outpatient pharmacy claims across all payer types, the study tracked over one million individuals attempting to fill two million brand-name prescriptions for the first time between January 2018 and September 2024. The results highlight a massive administrative hurdle: only sixty-eight percent of these initial prescription attempts were paid and dispensed on the first try. The remaining thirty-two percent were rejected at the pharmacy counter. Specifically, nearly fifteen percent were rejected due to complete formulary exclusion, and over seventeen percent were rejected because they required utilization management, such as prior authorization or step therapy. Alarmingly, these formulary-based rejections are becoming far more common, increasing by over sixty-seven percent over the six-year study period, rising from twenty-four percent of initial attempts in 2018 to nearly forty-one percent in 2024. The likelihood of rejection also depended heavily on the patient's insurance type. Rejections were most frequent among individuals enrolled in health insurance marketplace exchange plans, at nearly forty-nine percent, and Medicaid managed care plans, at nearly fifty percent. In contrast, stand-alone Medicare prescription drug plans and Medicare Advantage plans had lower rejection rates, at twenty-four percent and twenty percent, respectively. The clinical consequences of these rejections are profound. Among the patients whose initial prescriptions were rejected, only thirty-eight percent ultimately received the prescribed molecule within ninety days. Nearly half of the rejected patients, over forty-eight percent, received no medication at all in the same therapeutic class within that ninety-day window. Even for those who did eventually get their prescribed drug or a therapeutic substitute, the rejection caused an average treatment delay of over twelve days. This study underscores that formulary rejections are not just an administrative nuisance; they represent a major barrier to care that frequently leads to complete treatment abandonment or significant delays in initiating essential therapies.

Our second theme shifts focus to how we assess risk and manage patients over the long term, emphasizing that moving away from generic, population-level standards is essential for delivering safe, personalized clinical care. This principle is clearly illustrated in a large-scale population cohort study published in the BMJ, which examined how different fetal growth charts perform when identifying babies who are small or large for gestational age [4]. In England's National Health Service, clinicians routinely use fetal weight standards to identify pregnancies at risk due to restricted or accelerated growth. The researchers analyzed electronic health records from over three million singleton births across England between 2015 and 2025, evaluating seven different fetal weight standards. Six of these standards were unadjustable for maternal characteristics, including the Hadlock standard from the United States, the INTERGROWTH-twenty-first standards, the World Health Organization standard, the Fetal Medicine Foundation standard, and the GROW Lite standard. The seventh was the customized GROW standard, which adjusts fetal growth potential based on maternal height, weight, parity, and ethnic origin. The study revealed that "one-size-fits-all" unadjustable standards fail to account for the wide variation in maternal characteristics across different regions. Consequently, the rate of babies labeled as small for gestational age, defined as a birth weight below the tenth centile, varied wildly depending on which standard was used, ranging from just under six percent with the INTERGROWTH-twenty-first standard to nearly nineteen percent with the Fetal Medicine Foundation standard. Similarly, the rate of babies classified as large for gestational age, or above the ninetieth centile, ranged from approximately five percent using the Hadlock standard to nearly eighteen percent using INTERGROWTH-twenty-first. For babies born at term, the average small for gestational age rates were lowest for the INTERGROWTH standard at under five percent, and highest for the World Health Organization and Fetal Medicine Foundation standards, both at over seventeen percent. In contrast, the customized GROW standard, which accounts for maternal characteristics, designated twelve percent of term births as small for gestational age and had the narrowest variation across different regions. This suggests that unadjustable, generic growth charts systematically misclassify fetal growth, failing to identify truly growth-restricted or accelerated fetuses while over-identifying healthy babies. Implementing customized standards is therefore critical for personalized prenatal care and accurate clinical auditing.

The necessity of moving beyond generic, population-level approaches to achieve highly personalized care is also the central theme of a comprehensive clinical review in the BMJ focusing on systemic therapies for advanced prostate cancer [2]. Over the past two decades, the management of advanced prostate cancer has evolved rapidly, driven by improvements in metastatic disease detection, biomarker characterization, and targeted treatments. The review outlines the latest progress across three major disease states: high-risk biochemical recurrence, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. Earlier initiation of androgen receptor pathway inhibitors has significantly improved survival outcomes for patients with high-risk biochemical recurrence and metastatic hormone-sensitive disease. Meanwhile, patients with metastatic castration-resistant prostate cancer now represent a highly diverse population, and selecting the right therapy requires a deep understanding of their prior treatments and specific tumor biology. Advanced imaging techniques and genomic biomarkers are now standard tools to guide patient selection, allowing for highly personalized treatment regimens. Landmark clinical trials have firmly established the roles of chemotherapy, poly-ADP ribose polymerase, or PARP, inhibitors, and targeted radioligand therapy, such as Lutetium-177-PSMA-617, in this population. However, because these advanced therapies are successfully extending patients' lives, general medicine physicians are increasingly responsible for managing the long-term, cumulative toxicities of these treatments. The review highlights the critical importance of monitoring and managing treatment-related adverse events, including cardiac complications, hematologic toxicities, and the preservation of bone health. For general internists, this means that caring for a patient with advanced prostate cancer is no longer solely the domain of the oncologist; it requires active, multidisciplinary collaboration to mitigate the systemic side effects of lifelong androgen deprivation and targeted therapies.

If you only have time for one paper this week, make it the systematic review and network meta-analysis of weight-loss drugs published in the BMJ [1]. This landmark study provides the most comprehensive, head-to-head comparative data to date on nineteen different obesity pharmacotherapies, giving general medicine clinicians the precise efficacy and tolerability data they need to navigate shared decision-making in daily practice.

Here are the key takeaways from this week in General Medicine. First, when prescribing obesity medications, remember that while tirzepatide and CagriSema offer the greatest weight reduction at one year, they also carry the highest risks of gastrointestinal side effects, significant fatigue, and treatment discontinuation, meaning clinicians must carefully balance efficacy against tolerability. Second, subcutaneous semaglutide remains the only obesity pharmacotherapy with high-certainty evidence demonstrating reductions in all-cause mortality and myocardial infarction, although these benefits are primarily seen in high-risk cardiovascular populations. Third, be prepared for substantial administrative barriers when prescribing single-source branded drugs in the United States; over thirty percent of initial prescription attempts are rejected by insurers, and nearly half of those rejected patients end up receiving no medication in that therapeutic class within ninety days. Fourth, unadjustable, "one-size-fits-all" fetal growth charts fail to account for maternal diversity and systematically misclassify fetal growth, highlighting the urgent need for customized growth standards to ensure safe, personalized prenatal care. Finally, as advanced systemic therapies continue to extend survival in patients with advanced prostate cancer, general internists must actively collaborate with oncologists to monitor and manage long-term treatment complications, particularly cardiac toxicities and bone loss.

That's your roundup for This Week in General Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week. One more note before you go: only 4 new papers of note met the bar since the last update — a quieter stretch for new literature. Still worth revisiting from recent updates: Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection, in JAMA.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.